{"protocolSection": {"identificationModule": {"nctId": "NCT01928771", "orgStudyIdInfo": {"id": "D3250C00017"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma", "officialTitle": "A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist in Patients With Uncontrolled Asthma"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-09-19"}, "primaryCompletionDateStruct": {"date": "2016-04-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-08-16", "studyFirstSubmitQcDate": "2013-08-22", "studyFirstPostDateStruct": {"date": "2013-08-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-28", "resultsFirstSubmitQcDate": "2017-03-23", "resultsFirstPostDateStruct": {"date": "2017-05-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-03-23", "lastUpdatePostDateStruct": {"date": "2017-05-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma,", "Bronchial Diseases,", "Respiratory Tract Diseases,", "Lung Diseases,", "Obstructive Lung Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2681, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab 30 mg q.4 weeks", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Benralizumab 30 mg q.8 weeks", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 8 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered subcutaneously", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab subcutaneously on study week 0 until study week 44 inclusive.", "armGroupLabels": ["Benralizumab 30 mg q.4 weeks", "Benralizumab 30 mg q.8 weeks"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo subcutaneously on study week 0 until study week 44 inclusive.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}], "secondaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations", "description": "The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Number of Patients With >=1 Asthma Exacerbations", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Time to First Asthma Exacerbation", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Change in Asthma Rescue Medication", "description": "Change from baseline to week 48 in number of rescue medication use (puffs/day)", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Home Lung Function Assessment Based on Morning PEF", "description": "Change from baseline to week 48 in home lung function morning peak expiratory flow \\[PEF\\]", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Home Lung Function Assessment Based on Evening PEF", "description": "Change from baseline to week 48 in home lung function evening peak expiratory flow \\[PEF\\]", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Proportion of Night Awakening Due to Asthma", "description": "Change from baseline to Week 48 on proportion of night awakening due to asthma", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Pharmacokinetics of Benralizumab", "description": "Mean PK concentrations at each visit", "timeFrame": "Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56"}, {"measure": "Immunogenicity of Benralizumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.", "timeFrame": "Pre-treatment until end of follow-up"}, {"measure": "Extend of Exposure", "description": "Extend of exposure is defined as duration of treatment in days", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in AQLQ(S)+12", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Change From Baseline to Week 48 in EQ-5D-5L VAS", "description": "EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Work Productivity Loss Due to Asthma", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Mean Productivity Loss Due to Asthma in Classroom", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Number of Participants That Utilized Health Care Resources", "timeFrame": "Immediately following the first administration of study drug through Study Week 48."}, {"measure": "Patient and Clinician's Responder Assessment to Treatment", "description": "CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.", "timeFrame": "Immediately following the first administration of study drug through Study Week 48"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Written informed consent for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent\\[s\\]/guardian\\[s\\]) and according to international guidelines and/or applicable European Union guidelines.\n2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.\n3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (\\>250\u03bcg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1\n4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers.\n\n   * For subjects 18 years of age and older, the ICS dose must be \\>500 mcg/day fluticasone propionate dry powder formulation or equivalent daily.\n   * For subjects ages 12-17, the ICS dose must be \u2265500 mcg /day fluticasone propionate dry powder formulation or equivalent daily.\n\nExclusion criteria:\n\n1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)\n2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n   * Affect the safety of the patient throughout the study\n   * Influence the findings of the studies or their interpretations\n   * Impede the patient's ability to complete the entire duration of study\n3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period\n4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eugene R. Bleecker, MD, Professor of Medicine", "affiliation": "Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Foley", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 30.40659, "lon": -87.6836}}, {"facility": "Research Site", "city": "Huntsville", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "Research Site", "city": "Mobile", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Research Site", "city": "Scottsboro", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.67231, "lon": -86.03415}}, {"facility": "Research Site", "city": "Sheffield", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.76509, "lon": -87.69864}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Research Site", "city": "Bakersfield", "state": "California", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Beverly Hills", "state": "California", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "Research Site", "city": "Costa Mesa", "state": "California", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Research Site", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Huntington Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "Research Site", "city": "Los Angles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Research Site", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Research Site", "city": "San Jose", "state": "California", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Research Site", "city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"facility": "Research Site", "city": "Hartford", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.76371, "lon": -72.68509}}, {"facility": "Research Site", "city": "New Haven", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Research Site", "city": "Brandon", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "Research Site", "city": "Clearwater", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Research Site", "city": "Cutler Bay", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.5783, "lon": -80.3377}}, {"facility": "Research Site", "city": "DeLand", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Research Site", "city": "Gainesville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Hollywood", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Research Site", "city": "Homestead", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.46872, "lon": -80.47756}}, {"facility": "Research Site", "city": "Jackonsville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Research Site", "city": "Lynn Haven", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.24548, "lon": -85.64826}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "Research Site", "city": "Port Charlotte", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Research Site", "city": "Sebring", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.49559, "lon": -81.44091}}, {"facility": "Research Site", "city": "St Petersburg", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Vero Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.63864, "lon": -80.39727}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Albany", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Research Site", "city": "Gainesville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Research Site", "city": "Lawrenceville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Research Site", "city": "Gurnee", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 42.3703, "lon": -87.90202}}, {"facility": "Research Site", "city": "Normal", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Research Site", "city": "Iowa City", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Research Site", "city": "Fort Mitchell", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Research Site", "city": "Hazard", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.24954, "lon": -83.19323}}, {"facility": "Research Site", "city": "Louisville", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Research Site", "city": "Opelousas", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.53353, "lon": -92.08151}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "Gardner", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.57509, "lon": -71.99813}}, {"facility": "Research Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Research Site", "city": "Quincy", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.25288, "lon": -71.00227}}, {"facility": "Research Site", "city": "Farmington Hills", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.48531, "lon": -83.37716}}, {"facility": "Research Site", "city": "Rochester", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Research Site", "city": "St. Paul", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Research Site", "city": "Picayune", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"facility": "Research Site", "city": "Billings", "state": "Montana", "country": "United States", "geoPoint": {"lat": 45.78329, "lon": -108.50069}}, {"facility": "Research Site", "city": "Bellevue", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Sparks", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 39.53491, "lon": -119.75269}}, {"facility": "Research Site", "city": "Marlton", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.89122, "lon": -74.92183}}, {"facility": "Research Site", "city": "Northfield", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Research Site", "city": "Union", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.6976, "lon": -74.2632}}, {"facility": "Research Site", "city": "Albuquerque", "state": "New Mexico", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Hopewell Jct", "state": "New York", "country": "United States"}, {"facility": "Research Site", "city": "New York City", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Staten Island", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.56233, "lon": -74.13986}}, {"facility": "Research Site", "city": "Huntersville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.41069, "lon": -80.84285}}, {"facility": "Research Site", "city": "Shelby", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.29235, "lon": -81.53565}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Grand Forks", "state": "North Dakota", "country": "United States", "geoPoint": {"lat": 47.92526, "lon": -97.03285}}, {"facility": "Research Site", "city": "Oregon", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.64366, "lon": -83.48688}}, {"facility": "Research Site", "city": "Toledo", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Research Site", "city": "Wooster", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.80517, "lon": -81.93646}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Research Site", "city": "Erie", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 42.12922, "lon": -80.08506}}, {"facility": "Research Site", "city": "Feasterville", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.144, "lon": -75.00517}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Phoenixville", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.13038, "lon": -75.51491}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Warwick", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.7001, "lon": -71.41617}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "Easley", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.82984, "lon": -82.60152}}, {"facility": "Research Site", "city": "Hodges", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.28762, "lon": -82.24429}}, {"facility": "Research Site", "city": "Mt Pleasant", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Research Site", "city": "Rock Hill", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.92487, "lon": -81.02508}}, {"facility": "Research Site", "city": "Chattanooga", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Research Site", "city": "Germantown", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"facility": "Research Site", "city": "Allen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.10317, "lon": -96.67055}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Dickinson", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.46079, "lon": -95.05132}}, {"facility": "Research Site", "city": "Duncanville", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.6518, "lon": -96.90834}}, {"facility": "Research Site", "city": "Georgetown", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.63269, "lon": -97.67723}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "McAllen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 26.20341, "lon": -98.23001}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "Pharr", "state": "Texas", "country": "United States", "geoPoint": {"lat": 26.1948, "lon": -98.18362}}, {"facility": "Research Site", "city": "Plano", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Research Site", "city": "Sealy", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.78079, "lon": -96.15718}}, {"facility": "Research Site", "city": "Splendora", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.23299, "lon": -95.16104}}, {"facility": "Research Site", "city": "Orem", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.2969, "lon": -111.69465}}, {"facility": "Research Site", "city": "Provo", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.23384, "lon": -111.65853}}, {"facility": "Research Site", "city": "Salt Lake City", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Research Site", "city": "Abingdon", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.70983, "lon": -81.97735}}, {"facility": "Research Site", "city": "Hopewell", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.30432, "lon": -77.2872}}, {"facility": "Research Site", "city": "Morgantown", "state": "West Virginia", "country": "United States", "geoPoint": {"lat": 39.62953, "lon": -79.9559}}, {"facility": "Research Site", "city": "Greenfield", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Research Site", "city": "Bedford Park", "country": "Australia", "geoPoint": {"lat": -35.03333, "lon": 138.56667}}, {"facility": "Research Site", "city": "Box Hill", "country": "Australia", "geoPoint": {"lat": -37.81887, "lon": 145.12545}}, {"facility": "Research Site", "city": "Clayton", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "Research Site", "city": "Concord", "country": "Australia", "geoPoint": {"lat": -33.84722, "lon": 151.10381}}, {"facility": "Research Site", "city": "Frankston", "country": "Australia", "geoPoint": {"lat": -38.14458, "lon": 145.12291}}, {"facility": "Research Site", "city": "Nedlands", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Research Site", "city": "New Lambton Heights", "country": "Australia", "geoPoint": {"lat": -32.92466, "lon": 151.69364}}, {"facility": "Research Site", "city": "Parkville", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "Research Site", "city": "Prahran", "country": "Australia", "geoPoint": {"lat": -37.85114, "lon": 144.99318}}, {"facility": "Research Site", "city": "Randwick", "country": "Australia", "geoPoint": {"lat": -33.91439, "lon": 151.24895}}, {"facility": "Research Site", "city": "Woolloongabba", "country": "Australia", "geoPoint": {"lat": -27.48855, "lon": 153.03655}}, {"facility": "Research Site", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Rio de Janeiro", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Research Site", "city": "Santo Andr\u00e9", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Research Site", "city": "Sorocaba", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Research Site", "city": "S\u00e3o Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Research Site", "city": "Dupnitsa", "country": "Bulgaria", "geoPoint": {"lat": 42.26667, "lon": 23.11667}}, {"facility": "Research Site", "city": "Pernik", "country": "Bulgaria", "geoPoint": {"lat": 42.6, "lon": 23.03333}}, {"facility": "Research Site", "city": "Pleven", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"facility": "Research Site", "city": "Ruse", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Samokov", "country": "Bulgaria", "geoPoint": {"lat": 42.337, "lon": 23.5528}}, {"facility": "Research Site", "city": "Sliven", "country": "Bulgaria", "geoPoint": {"lat": 42.68583, "lon": 26.32917}}, {"facility": "Research Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Stara Zagora", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"facility": "Research Site", "city": "Varna", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"facility": "Research Site", "city": "Velingrad", "country": "Bulgaria", "geoPoint": {"lat": 42.02754, "lon": 23.99155}}, {"facility": "Research Site", "city": "Yambol", "country": "Bulgaria", "geoPoint": {"lat": 42.48333, "lon": 26.5}}, {"facility": "Research Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Research Site", "city": "Jindrichuv Hradec", "country": "Czech Republic", "geoPoint": {"lat": 49.14404, "lon": 15.00301}}, {"facility": "Research Site", "city": "Karlovy Vary", "country": "Czech Republic", "geoPoint": {"lat": 50.23271, "lon": 12.87117}}, {"facility": "Research Site", "city": "Ostrava", "country": "Czech Republic", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"facility": "Research Site", "city": "Pardubice", "country": "Czech Republic", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"facility": "Research Site", "city": "Plzen", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Research Site", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Rokycany", "country": "Czech Republic", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Research Site", "city": "Strakonice", "country": "Czech Republic", "geoPoint": {"lat": 49.26141, "lon": 13.90237}}, {"facility": "Research Site", "city": "Teplice", "country": "Czech Republic", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Research Site", "city": "Brest Cedex", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Research Site", "city": "Clermont Ferrand", "country": "France", "geoPoint": {"lat": 45.77966, "lon": 3.08628}}, {"facility": "Research Site", "city": "Dijon Cedex", "country": "France", "geoPoint": {"lat": 47.31667, "lon": 5.01667}}, {"facility": "Research Site", "city": "Le Kremlin Bic\u00eatre", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Research Site", "city": "Le Mans Cedex", "country": "France", "geoPoint": {"lat": 48.0, "lon": 0.2}}, {"facility": "Research Site", "city": "Lyon Cedex 4", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Research Site", "city": "Marseille", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Pau Cedex", "country": "France", "geoPoint": {"lat": 43.3, "lon": -0.36667}}, {"facility": "Research Site", "city": "Pringy Cedex", "country": "France", "geoPoint": {"lat": 45.94622, "lon": 6.12608}}, {"facility": "Research Site", "city": "Saint Pierre", "country": "France"}, {"facility": "Research Site", "city": "Strasbourg Cedex", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Toulouse", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Research Site", "city": "Bari", "country": "Italy", "geoPoint": {"lat": 41.11148, "lon": 16.8554}}, {"facility": "Research Site", "city": "Bologna", "country": "Italy", "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "Research Site", "city": "Catania", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Research Site", "city": "Cona", "country": "Italy", "geoPoint": {"lat": 44.80583, "lon": 11.7069}}, {"facility": "Research Site", "city": "Firenze", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Research Site", "city": "Foggia", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "Research Site", "city": "Legnago", "country": "Italy", "geoPoint": {"lat": 45.19365, "lon": 11.30227}}, {"facility": "Research Site", "city": "Milano", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Research Site", "city": "Napoli", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Research Site", "city": "Palermo", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Research Site", "city": "Pavia", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"facility": "Research Site", "city": "Perugia", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "Research Site", "city": "Pisa", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "San Pietro Vernotico", "country": "Italy", "geoPoint": {"lat": 40.4889, "lon": 17.99752}}, {"facility": "Research Site", "city": "Torino", "country": "Italy", "geoPoint": {"lat": 45.07049, "lon": 7.68682}}, {"facility": "Research Site", "city": "Verona", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Research Site", "city": "Anyang-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.3925, "lon": 126.92694}}, {"facility": "Research Site", "city": "Bucheon-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Research Site", "city": "Cheongju-si", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Research Site", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Research Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Jeju-si", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Morelia", "country": "Mexico", "geoPoint": {"lat": 19.70078, "lon": -101.18443}}, {"facility": "Research Site", "city": "Cusco", "country": "Peru", "geoPoint": {"lat": -13.52264, "lon": -71.96734}}, {"facility": "Research Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Research Site", "city": "Surco", "country": "Peru"}, {"facility": "Research Site", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Dobre Miasto", "country": "Poland", "geoPoint": {"lat": 53.98668, "lon": 20.39749}}, {"facility": "Research Site", "city": "Gda\u0144sk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Gi\u017cycko", "country": "Poland", "geoPoint": {"lat": 54.03811, "lon": 21.76441}}, {"facility": "Research Site", "city": "Grodzisk Mazowiecki", "country": "Poland", "geoPoint": {"lat": 52.10387, "lon": 20.6337}}, {"facility": "Research Site", "city": "Ko\u015bcian", "country": "Poland", "geoPoint": {"lat": 52.08829, "lon": 16.64866}}, {"facility": "Research Site", "city": "Legnica", "country": "Poland", "geoPoint": {"lat": 51.21006, "lon": 16.1619}}, {"facility": "Research Site", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Pozna\u0144", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Proszowice", "country": "Poland", "geoPoint": {"lat": 50.19275, "lon": 20.28909}}, {"facility": "Research Site", "city": "Rzesz\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "Research Site", "city": "Sosnowiec", "country": "Poland", "geoPoint": {"lat": 50.28682, "lon": 19.10385}}, {"facility": "Research Site", "city": "Wo\u0142omin", "country": "Poland", "geoPoint": {"lat": 52.34006, "lon": 21.24207}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Zgierz", "country": "Poland", "geoPoint": {"lat": 51.85561, "lon": 19.40623}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "Chelyabinsk", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Research Site", "city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Ivanovo", "country": "Russian Federation", "geoPoint": {"lat": 56.99719, "lon": 40.97139}}, {"facility": "Research Site", "city": "Izhevsk", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Research Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Nizhny Novgorod", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Research Site", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Pyatigorsk", "country": "Russian Federation", "geoPoint": {"lat": 44.04861, "lon": 43.05944}}, {"facility": "Research Site", "city": "Rostov-on-Don", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Research Site", "city": "Ryazan", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "Research Site", "city": "Saint - Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saratov", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Research Site", "city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Research Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "StPetersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Research Site", "city": "Vladikavkaz", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Research Site", "city": "Vladimir", "country": "Russian Federation", "geoPoint": {"lat": 56.13655, "lon": 40.39658}}, {"facility": "Research Site", "city": "Volgograd", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Research Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Research Site", "city": "Yekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Benoni", "country": "South Africa", "geoPoint": {"lat": -26.18848, "lon": 28.32078}}, {"facility": "Research Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Mowbray", "country": "South Africa", "geoPoint": {"lat": -33.94802, "lon": 18.47333}}, {"facility": "Research Site", "city": "Stanger", "country": "South Africa", "geoPoint": {"lat": -29.32816, "lon": 31.28954}}, {"facility": "Research Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Research Site", "city": "Lugo", "country": "Spain", "geoPoint": {"lat": 43.00992, "lon": -7.55602}}, {"facility": "Research Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Research Site", "city": "M\u00e1laga", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Research Site", "city": "Oviedo", "country": "Spain", "geoPoint": {"lat": 43.36029, "lon": -5.84476}}, {"facility": "Research Site", "city": "Palma de Mallorca", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "Research Site", "city": "Sagunto(Valencia)", "country": "Spain"}, {"facility": "Research Site", "city": "Salamanca", "country": "Spain", "geoPoint": {"lat": 40.96882, "lon": -5.66388}}, {"facility": "Research Site", "city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Research Site", "city": "Adana", "country": "Turkey", "geoPoint": {"lat": 37.00167, "lon": 35.32889}}, {"facility": "Research Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Antalya", "country": "Turkey", "geoPoint": {"lat": 36.90812, "lon": 30.69556}}, {"facility": "Research Site", "city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "Izmir", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Research Site", "city": "Kocaeli", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}, {"facility": "Research Site", "city": "Mersin", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Research Site", "city": "Birmingham", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Research Site", "city": "Bradford", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Research Site", "city": "Cambridge", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Research Site", "city": "Chertsey", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "Research Site", "city": "Chester", "country": "United Kingdom", "geoPoint": {"lat": 53.1905, "lon": -2.89189}}, {"facility": "Research Site", "city": "Chippenham", "country": "United Kingdom", "geoPoint": {"lat": 51.46, "lon": -2.12472}}, {"facility": "Research Site", "city": "Cottingham", "country": "United Kingdom", "geoPoint": {"lat": 52.50243, "lon": -0.7554}}, {"facility": "Research Site", "city": "Darlington", "country": "United Kingdom", "geoPoint": {"lat": 54.52429, "lon": -1.55039}}, {"facility": "Research Site", "city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "High Heaton/Newcastle upon Tyn", "country": "United Kingdom"}, {"facility": "Research Site", "city": "Leeds", "country": "United Kingdom", "geoPoint": {"lat": 53.79648, "lon": -1.54785}}, {"facility": "Research Site", "city": "Liverpool", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Research Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "Maidstone", "country": "United Kingdom", "geoPoint": {"lat": 51.26667, "lon": 0.51667}}, {"facility": "Research Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Research Site", "city": "Nottingham", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}, {"facility": "Research Site", "city": "Plymouth", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "Research Site", "city": "Portsmouth", "country": "United Kingdom", "geoPoint": {"lat": 50.79899, "lon": -1.09125}}, {"facility": "Research Site", "city": "Soham", "country": "United Kingdom", "geoPoint": {"lat": 52.33543, "lon": 0.33654}}, {"facility": "Research Site", "city": "Somerset", "country": "United Kingdom"}, {"facility": "Research Site", "city": "Stevenage", "country": "United Kingdom", "geoPoint": {"lat": 51.90224, "lon": -0.20256}}, {"facility": "Research Site", "city": "Stockton", "country": "United Kingdom", "geoPoint": {"lat": 54.56848, "lon": -1.3187}}, {"facility": "Research Site", "city": "Hanoi", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"facility": "Research Site", "city": "Ho Chi Minh", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}, "referencesModule": {"references": [{"pmid": "35287231", "type": "DERIVED", "citation": "Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14."}, {"pmid": "32334141", "type": "DERIVED", "citation": "Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22."}, {"pmid": "31836949", "type": "DERIVED", "citation": "Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14."}, {"pmid": "31626906", "type": "DERIVED", "citation": "Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15."}, {"pmid": "30802500", "type": "DERIVED", "citation": "Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23."}, {"pmid": "30139780", "type": "DERIVED", "citation": "Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct."}, {"pmid": "30077185", "type": "DERIVED", "citation": "DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4."}, {"pmid": "29409951", "type": "DERIVED", "citation": "Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1."}, {"pmid": "27609408", "type": "DERIVED", "citation": "Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5."}], "seeAlsoLinks": [{"label": "D3250C00017CSP3redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1845&filename=D3250C00017_Revised_CSP_SIROCCO.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "2681 participants signed informed consent form, 2232 participants entered screening/run-in period,1205 participants were randomised to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 1205 patients randomised, 1204 patients received treatment with the study drug.", "groups": [{"id": "FG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "FG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "FG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "400"}, {"groupId": "FG001", "numSubjects": "398"}, {"groupId": "FG002", "numSubjects": "407"}]}, {"type": "Received Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "399"}, {"groupId": "FG001", "numSubjects": "398"}, {"groupId": "FG002", "numSubjects": "407"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "354"}, {"groupId": "FG001", "numSubjects": "358"}, {"groupId": "FG002", "numSubjects": "367"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "40"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "Study-Specific Withdrawal Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Other Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Severe Non-Compliance to Protocol", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "BG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "BG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "399"}, {"groupId": "BG001", "value": "398"}, {"groupId": "BG002", "value": "407"}, {"groupId": "BG003", "value": "1204"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.1", "spread": "13.4"}, {"groupId": "BG001", "value": "47.6", "spread": "14.5"}, {"groupId": "BG002", "value": "48.7", "spread": "14.9"}, {"groupId": "BG003", "value": "48.8", "spread": "14.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "275"}, {"groupId": "BG001", "value": "252"}, {"groupId": "BG002", "value": "269"}, {"groupId": "BG003", "value": "796"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "124"}, {"groupId": "BG001", "value": "146"}, {"groupId": "BG002", "value": "138"}, {"groupId": "BG003", "value": "408"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.73", "lowerLimit": "0.60", "upperLimit": "0.89"}, {"groupId": "OG001", "value": "0.65", "lowerLimit": "0.53", "upperLimit": "0.80"}, {"groupId": "OG002", "value": "1.33", "lowerLimit": "1.12", "upperLimit": "1.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate ratio", "paramValue": "0.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.42", "ciUpperLimit": "0.71"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate ratio", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "0.64"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL", "description": "The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "lowerLimit": "0.65", "upperLimit": "1.11"}, {"groupId": "OG001", "value": "1.00", "lowerLimit": "0.78", "upperLimit": "1.28"}, {"groupId": "OG002", "value": "1.21", "lowerLimit": "0.96", "upperLimit": "1.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.047", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate ratio", "paramValue": "0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5", "ciUpperLimit": "1.0"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.268", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Rate ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "1.16"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations", "description": "The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.07", "upperLimit": "0.16"}, {"groupId": "OG001", "value": "0.06", "lowerLimit": "0.04", "upperLimit": "0.11"}, {"groupId": "OG002", "value": "0.18", "lowerLimit": "0.13", "upperLimit": "0.25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.053", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS", "paramType": "Rate ratio", "paramValue": "0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.01"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS", "paramType": "Rate ratio", "paramValue": "0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "0.67"}]}, {"type": "SECONDARY", "title": "Number of Patients With >=1 Asthma Exacerbations", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "100", "spread": "84.227"}, {"groupId": "OG001", "value": "93", "spread": "72.002"}, {"groupId": "OG002", "value": "135", "spread": "74.434"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Proportion of patients with \\>=1 asthma exacerbation", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region, number of exacerbations in the previous year, use of OCS", "paramType": "Odds Ratio (OR)", "paramValue": "0.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "0.78"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Proportion of patients with \\>=1 asthma exacerbation", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.01", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region, number of exacerbations from the previous year, use of OCS", "paramType": "Odds Ratio (OR)", "paramValue": "0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.43", "ciUpperLimit": "0.90"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "84.227", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Median time is not estimable due to less than 50% patients had exacerbations occurred."}, {"groupId": "OG001", "value": "NA", "spread": "72.002", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Median time is not estimable due to less than 50% patients had exacerbations occurred."}, {"groupId": "OG002", "value": "300", "spread": "74.434", "lowerLimit": "199", "upperLimit": "NA", "comment": "Upper 95% CI for median is not estimable due to the curve representing the upper confidence limit of the survival function is above 50%"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Time to first exacerbation", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "statisticalComment": "Model includes treatment, number of exacerbations in the previous year, region, use of OCS", "paramType": "Hazard Ratio (HR)", "paramValue": "0.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.49", "ciUpperLimit": "0.82"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Time to first exacerbation", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "statisticalComment": "Model includes treatment, number of exacerbations from the previous year, region, use of OCS", "paramType": "Hazard Ratio (HR)", "paramValue": "0.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "0.78"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL", "populationDescription": "Full analysis set, Baseline eosinopiles \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "235"}, {"groupId": "OG002", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.353", "spread": "0.503"}, {"groupId": "OG001", "value": "0.398", "spread": "0.546"}, {"groupId": "OG002", "value": "0.237", "spread": "0.508"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.022", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.106", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.016", "ciUpperLimit": "0.196"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.159", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.068", "ciUpperLimit": "0.249"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL", "populationDescription": "Full analysis set, Baseline eosinopiles \\<300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.115", "spread": "0.417"}, {"groupId": "OG001", "value": "0.238", "spread": "0.483"}, {"groupId": "OG002", "value": "0.140", "spread": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.644", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.025", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.134", "ciUpperLimit": "0.083"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.057", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.102", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.003", "ciUpperLimit": "0.208"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.15", "spread": "1.31"}, {"groupId": "OG001", "value": "-1.34", "spread": "1.27"}, {"groupId": "OG002", "value": "-1.03", "spread": "1.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.442", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "0.12"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.012", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.45", "ciUpperLimit": "-0.06"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "spread": "1.19"}, {"groupId": "OG001", "value": "-1.04", "spread": "1.24"}, {"groupId": "OG002", "value": "-0.78", "spread": "0.99"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.169", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "0.08"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.043", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "-0.01"}]}, {"type": "SECONDARY", "title": "Change in Asthma Rescue Medication", "description": "Change from baseline to week 48 in number of rescue medication use (puffs/day)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.74", "spread": "4.29"}, {"groupId": "OG001", "value": "-2.78", "spread": "3.90"}, {"groupId": "OG002", "value": "-2.18", "spread": "4.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.16", "ciUpperLimit": "0.10"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.081", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.21", "ciUpperLimit": "0.07"}]}, {"type": "SECONDARY", "title": "Home Lung Function Assessment Based on Morning PEF", "description": "Change from baseline to week 48 in home lung function morning peak expiratory flow \\[PEF\\]", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "205"}, {"groupId": "OG001", "value": "181"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.857", "spread": "84.227"}, {"groupId": "OG001", "value": "36.994", "spread": "72.002"}, {"groupId": "OG002", "value": "22.059", "spread": "74.434"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Morning PEF change from baseline to Week 48", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "23.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.20", "ciUpperLimit": "37.43"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Morning PEF change from baseline to Week 48", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.025", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "16.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.08", "ciUpperLimit": "30.83"}]}, {"type": "SECONDARY", "title": "Home Lung Function Assessment Based on Evening PEF", "description": "Change from baseline to week 48 in home lung function evening peak expiratory flow \\[PEF\\]", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "187"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.806", "spread": "86.271"}, {"groupId": "OG001", "value": "33.460", "spread": "74.017"}, {"groupId": "OG002", "value": "14.784", "spread": "68.799"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Evening PEF change from baseline to Week 48", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "21.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.86", "ciUpperLimit": "35.65"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Evening PEF change from baseline to Week 48", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "19.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.09", "ciUpperLimit": "33.28"}]}, {"type": "SECONDARY", "title": "Proportion of Night Awakening Due to Asthma", "description": "Change from baseline to Week 48 on proportion of night awakening due to asthma", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion of nights", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "193"}, {"groupId": "OG002", "value": "195"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.314", "spread": "0.366"}, {"groupId": "OG001", "value": "-0.380", "spread": "0.385"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.344"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.964", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.04"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.012", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "-0.01"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "191"}, {"groupId": "OG002", "value": "186"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "spread": "1.18"}, {"groupId": "OG001", "value": "-1.47", "spread": "1.05"}, {"groupId": "OG002", "value": "-1.12", "spread": "1.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.111", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.34", "ciUpperLimit": "0.04"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "-0.10"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "94"}, {"groupId": "OG002", "value": "97"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "1.07"}, {"groupId": "OG001", "value": "-1.14", "spread": "1.11"}, {"groupId": "OG002", "value": "-0.89", "spread": "1.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.99", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "0.27"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.107", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "0.05"}]}, {"type": "SECONDARY", "title": "Pharmacokinetics of Benralizumab", "description": "Mean PK concentrations at each visit", "populationDescription": "PK analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "399"}, {"groupId": "OG001", "value": "391"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline (n=395, 386)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}]}]}, {"title": "Week 4 (n=393, 375)", "categories": [{"measurements": [{"groupId": "OG000", "value": "632.84", "spread": "152.14"}, {"groupId": "OG001", "value": "629.89", "spread": "169.22"}]}]}, {"title": "Week 4 day 6 (n=54, 63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1368.98", "spread": "633.33"}, {"groupId": "OG001", "value": "1273.7", "spread": "688.20"}]}]}, {"title": "Week 8 (n=377, 366)", "categories": [{"measurements": [{"groupId": "OG000", "value": "916.25", "spread": "142.53"}, {"groupId": "OG001", "value": "881.57", "spread": "156.12"}]}]}, {"title": "Week 16 (n=358, 350)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1024.26", "spread": "174.08"}, {"groupId": "OG001", "value": "250.84", "spread": "228.25"}]}]}, {"title": "Week 24 (n=349, 344)", "categories": [{"measurements": [{"groupId": "OG000", "value": "926.62", "spread": "231.75"}, {"groupId": "OG001", "value": "184.08", "spread": "298.92"}]}]}, {"title": "Week 32 (n=260, 267)", "categories": [{"measurements": [{"groupId": "OG000", "value": "853.67", "spread": "248.6"}, {"groupId": "OG001", "value": "152.73", "spread": "394.18"}]}]}, {"title": "Week 40 (n=328, 333)", "categories": [{"measurements": [{"groupId": "OG000", "value": "967.15", "spread": "218.32"}, {"groupId": "OG001", "value": "157.22", "spread": "364.6"}]}]}, {"title": "Week 48 (n=333, 333)", "categories": [{"measurements": [{"groupId": "OG000", "value": "864.37", "spread": "283.87"}, {"groupId": "OG001", "value": "162.51", "spread": "352.46"}]}]}, {"title": "Week 56 (n=63, 67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.7", "spread": "833.91"}, {"groupId": "OG001", "value": "6.66", "spread": "321.88"}]}]}]}, {"type": "SECONDARY", "title": "Immunogenicity of Benralizumab", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.", "populationDescription": "Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398. However, data were only available for 402 patients in q.4, and 393 patients in q.8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Pre-treatment until end of follow-up", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "402"}, {"groupId": "OG001", "value": "393"}, {"groupId": "OG002", "value": "407"}]}], "classes": [{"title": "Positive at any visit (n=402, 393, 407)", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Base- and post baseline positive (n=393, 381, 396)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "Only post baseline positive (n=396, 389, 402)", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "Persistently positive (n=396, 389, 402)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "39"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Transiently positive (n=396, 389, 402)", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Only baseline positive (n=399, 385, 401)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Extend of Exposure", "description": "Extend of exposure is defined as duration of treatment in days", "populationDescription": "Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "403"}, {"groupId": "OG001", "value": "394"}, {"groupId": "OG002", "value": "407"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "285.86", "spread": "67.446"}, {"groupId": "OG001", "value": "288.02", "spread": "66.683"}, {"groupId": "OG002", "value": "289.38", "spread": "61.527"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in AQLQ(S)+12", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "187"}, {"groupId": "OG002", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.44", "spread": "1.18"}, {"groupId": "OG001", "value": "1.56", "spread": "1.17"}, {"groupId": "OG002", "value": "1.25", "spread": "1.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.081", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.37"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment", "paramType": "Mean Difference (Final Values)", "paramValue": "0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.1", "ciUpperLimit": "0.5"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Week 48 in EQ-5D-5L VAS", "description": "EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "186"}, {"groupId": "OG002", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.5", "spread": "21.82"}, {"groupId": "OG001", "value": "16.5", "spread": "23.66"}, {"groupId": "OG002", "value": "12.5", "spread": "21.41"}]}]}]}, {"type": "SECONDARY", "title": "Mean Work Productivity Loss Due to Asthma", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL for patients who employed", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of productivity loss", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.31", "spread": "24.169"}, {"groupId": "OG001", "value": "26.11", "spread": "23.06"}, {"groupId": "OG002", "value": "35.36", "spread": "24.537"}]}]}]}, {"type": "SECONDARY", "title": "Mean Productivity Loss Due to Asthma in Classroom", "description": "WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL who attending classes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of productivity loss", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.97", "spread": "25.311"}, {"groupId": "OG001", "value": "27.17", "spread": "38.456"}, {"groupId": "OG002", "value": "49.1", "spread": "25.801"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants That Utilized Health Care Resources", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300=/uL", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "Hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "20"}]}]}, {"title": "Emergency department visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "26"}]}]}, {"title": "Unscheduled outpatient visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "87"}, {"groupId": "OG002", "value": "109"}]}]}, {"title": "Home visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Telephone calls", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "62"}]}]}, {"title": "Ambulance transports", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Patient and Clinician's Responder Assessment to Treatment", "description": "CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the first administration of study drug through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously."}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously."}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "CGIC improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "76"}, {"groupId": "OG002", "value": "88"}]}]}, {"title": "CGIC much improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": "CGIC very much improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "CGIC total responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "151"}]}]}, {"title": "PGIC improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "91"}]}]}, {"title": "PGIC much improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "65"}]}]}, {"title": "PGIC very much improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "PGIC total responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "165"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "167"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "description": "There were 400 patients randomized to Benra q.4, and 398 patients randomized to Benra q.8. One patient in Benra q.4 was never treated. In addition, 4 patients who were randomized to q.8 group, but were treated with q.4 schedule. So 403 patients were treated with q.4 regimen, and 394 patients were treated with q.8 regimen.", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered every 4 weeks subcutaneously.", "seriousNumAffected": 51, "seriousNumAtRisk": 403, "otherNumAffected": 214, "otherNumAtRisk": 403}, {"id": "EG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered every 8 weeks subcutaneously.", "seriousNumAffected": 54, "seriousNumAtRisk": 394, "otherNumAffected": 199, "otherNumAtRisk": 394}, {"id": "EG002", "title": "Placebo", "description": "Placebo administered subcutaneously", "seriousNumAffected": 58, "seriousNumAtRisk": 407, "otherNumAffected": 219, "otherNumAtRisk": 407}], "seriousEvents": [{"term": "Hypercoagulation", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Optic nerve disorder", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Volvulus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Allergic granulomatous angiitis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Contrast media allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Bullous impetigo", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Parotitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 407}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Pneumonia pneumococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Pneumonia viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Urinary tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 407}]}, {"term": "Urinary tract infection enterococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Vestibular neuronitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Femoral neck fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Muscle rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Post procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Foot deformity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Intervertebral disc degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 407}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Vertebral foraminal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Adenolymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Meningioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Ovarian epithelial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Aphonia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Cerebral venous thrombosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 29, "numAffected": 23, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 33, "numAffected": 24, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 42, "numAffected": 32, "numAtRisk": 407}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 407}]}, {"term": "Sinus polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Erythema nodosum", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Rash papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Urticaria papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 407}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 407}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 8, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 407}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 16, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 19, "numAffected": 12, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 407}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 15, "numAffected": 11, "numAtRisk": 407}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 27, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 22, "numAffected": 19, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 41, "numAffected": 30, "numAtRisk": 407}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 10, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 407}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 15, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 21, "numAffected": 19, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 31, "numAffected": 23, "numAtRisk": 407}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 62, "numAffected": 47, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 69, "numAffected": 47, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 64, "numAffected": 49, "numAtRisk": 407}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 17, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 24, "numAffected": 23, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 20, "numAffected": 14, "numAtRisk": 407}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 17, "numAffected": 15, "numAtRisk": 407}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 18, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 34, "numAffected": 22, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 43, "numAffected": 29, "numAtRisk": 407}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 74, "numAffected": 45, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 51, "numAffected": 32, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 73, "numAffected": 37, "numAtRisk": 407}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 20, "numAffected": 18, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 19, "numAffected": 12, "numAtRisk": 407}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 15, "numAffected": 15, "numAtRisk": 407}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 407}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 38, "numAffected": 31, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 61, "numAffected": 37, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 28, "numAffected": 21, "numAtRisk": 407}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 64, "numAffected": 48, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 38, "numAffected": 27, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 102, "numAffected": 60, "numAtRisk": 407}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 15, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 15, "numAffected": 11, "numAtRisk": 407}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 403}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 394}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 407}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Mitchell Goldman , Medical Science Director", "organization": "AstraZeneca", "email": "Mitchell.Goldman@astrazeneca.com", "phone": "+1 301 398 0323"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}